Gestational Trophoblastic Disease: Current Evaluation and Management

Written By: user

IJCP Editorial Team

Published On: 28 May, 2022 1:32 PM | Updated On: 15 May, 2024 11:57 AM

Gestational Trophoblastic Disease: Current Evaluation and Management

The Majority of the women suffering from any form of gestational trophoblastic disease can be successfully diagnosed and treated with preservation of their reproductive function.
Managing molar pregnancies properly is crucial in diminishing the acute complications and identifying postmolar gestational trophoblastic neoplasia quickly.
Individualizing treatment for women suffering from any form of gestational trophoblastic neoplasia is crucial. This individualization must be based on known risk factors, usage of less-toxic therapy for patients with low-risk diseases and aggressive multiagent therapy for those with high-risk diseases.
Only the centers or consultants having experience in the complex multimodality treatment must manage Patients with high-risk gestational trophoblastic neoplasia.

SOURCE- Soper JT. Gestational Trophoblastic Disease: Current Evaluation and Management [published correction appears in Obstet Gynecol. 2022 Jan 1;139(1):149]. Obstet Gynecol. 2021;137(2):355-370. doi:10.1097/AOG.0000000000004240

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.